Loading clinical trials...

The Efficacy of Oral Antiseptics Against COVID-19 | Clinical Trials | Clareo Health

COMPLETEDPHASE4

The Efficacy of Oral Antiseptics Against COVID-19

The Effectiveness of Oral Antiseptics on the Intraoral Viral Load of SARS-CoV-2

NCT05214196•Ataturk University

Summary

In a study conducted on 75 COVID-19 patients, the effect of SARS-CoV-2 on viral load was investigated as a result of the use of hypochlorous acid and povidone-iodine as an oral antiseptic.

Detailed Description

Before and 30 minutes after rinsing with mouth antiseptics, the participants were asked to rinse the mouth and throat for 30 seconds with 0.9% isotonic saline. The sample was sputtered into a sterile plastic container. The participants were grouped according to the type of oral antiseptics used. The effectiveness of SARS-CoV-2 viral load was investigated by rinsing the mouth and throat for 30 seconds with 20 ml of hypochlorous acid, povidone-iodine, and isotonic saline. Viral load was analyzed by RT-PCR analysis. The results were evaluated by statistical analysis.

Eligibility

Age

18 - No limit years

Sex

ALL

Healthy Volunteers

Inclusion Criteria

•Positive SARS-CoV-2 RT-PCR result,
•Adult hospitalized patient,
•The participants have the physical and psychological ability to follow the instructions in the study.

Exclusion Criteria

•Patients intubated and supported by a mechanical respirator,
•Severe acute or chronic medical or psychiatric condition,
•History of significant adverse effects following use of oral hygiene products such as toothpaste and mouth rinses,
•Active uncontrolled thyroid disease,
•Developmental/cognitive disability,
•Pregnancy,
•Undergoing radioactive iodine therapy.

Locations (1)

Atatürk University Faculty of Dentistry

Erzurum, Turkey (Türkiye)

Key Dates

Start Date

September 1, 2021

Primary Completion Date

December 1, 2021

Completion Date

December 7, 2021

Last Updated

February 11, 2022

Enrollment

ACTUAL participants

Conditions

COVID-19

Interventions

Hypochlorous Acid 0.02% Soln,Top (Crystaline) (HClO)

DRUG

Improving Post COVID-19 Syndrome With Hyperbaric Oxygen Treatments

NCT06082518

Post COVID-19 ConditionPost-COVID-19 Syndrome+4 more

View study

RECRUITINGPHASE1

A Safety and Immunogenicity Trial of Boost-2867 Vaccine, Via Intranasal and Intramuscular Routes

NCT07221162

COVID-19

View study

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: February 11, 2022Data synced to Clareo: March 29, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions

The Efficacy of Oral Antiseptics Against COVID-19

Inclusion Criteria

Exclusion Criteria

Improving Post COVID-19 Syndrome With Hyperbaric Oxygen Treatments

A Safety and Immunogenicity Trial of Boost-2867 Vaccine, Via Intranasal and Intramuscular Routes

Randomized Double-Blind Placebo-Controlled Trial EValuating Baricitinib on PERSistent NEurologic and Cardiopulmonary Symptoms of Long COVID

A Study to Learn About a Study Medicine Called Ibuzatrelvir in Adult and Adolescent Patients With COVID-19 Who Are Not Hospitalized But Are at Risk For Severe Disease

Dime La VerDAD: Verify, Debunk, and Disseminate

Positron Emission Tomography (PET) Imaging of Thrombosis